Inspira Technologies Oxy B.H.N. Ltd. (IINN) is currently priced at 48 cents, showing a decrease of -2.9 cents (-5.7%) from the previous close of 50.9 cents. The trading volume stands at $273,146, a significant increase of 39.7% compared to the average.
IINN has experienced a three-day streak of declining prices, with a total absolute change of -10.69 cents (-18.21%). The streak began at 58.69 cents.
The latest quarterly earnings report of IINN, announced on Tuesday, March 31st, revealed a consensus estimate EPS of -0.2. The consensus estimate revenue was reported at $200,000.
Key financial metrics for IINN include a quick ratio of 1.3, cash ratio of 1.12, debt ratio of 8.99, and debt equity ratio of 20.66. Notably, the company exhibits a net debt of -$2.68 million.
IINN's financial snapshot displays total assets of $5.34 million, total liabilities of $3 million, and common stock valued at $82.12 million. The company holds cash and cash equivalents totaling $3.16 million.
In summary, Inspira Technologies Oxy B.H.N. Ltd. is currently facing a price decline streak amid increased trading volume, while maintaining a strong balance sheet with notable financial ratios.
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.